ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer&#39;s Disease

sabirnetug IV (ACU193 IV) - Acumen Pharma

https://www.ctad-alzheimer.com/files/files/PROGRAM_CTAD2024_WEB%20October%2018.pdf

Todd Feaster 1; Karen Sundell 1; Maddelyn Hyland 1; Gopalan Sethuraman 1; Vladmir Skljarevski 1; June Kaplow 1; Robert A. Dean 1; Jasna Jerecic 1; Eric Siemers 1

Sep 24, 2024